Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

BMC Gastroenterology

Research Article

Adamantia Zizi-Serbetzoglou¹  Ioannis Koutsounas²  Stamatios Theocharis²  Nicolaos Tsoukalas²  Efstratios Patsouris²  Constantinos Giaginis³  Christos Damaskos⁴  Gregorios Kouraklis⁴ 

[1] Department of Pathology, Tzaneio General Hospital, Piraeus, Greece;First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece;First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece;Department of Food Science and Nutrition, School of Environment, University of the Aegean, Mitropoliti Ioakeim 2, 81400, Myrina, Limnos, Greece;Second Department of Propedeutic Surgery, Medical School, University of Athens, Athens, Greece;

关键词: Histone deacetylase;    Pancreatic adenocarcinoma;    Immunohistochemistry;    Clinicopathological parameters;    Patients’ survival;   

DOI  :  10.1186/s12876-015-0379-y

 received in 2015-07-01, accepted in 2015-10-15,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundHistone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, −2, −4 and −6 protein expression in pancreatic adenocarcinoma.MethodsHDAC-1, −2, −4 and −6 protein expression was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was statistically analyzed with clinicopathological characteristics and patients’ survival.ResultsEnhanced HDAC-1 expression was significantly associated with increased tumor proliferative capacity (p = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632). Elevated HDAC-4 expression was significantly associated with the absence of organ metastases (p = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferative capacity (p = 0.0576). Enhanced HDAC-6 expression was significantly associated with earlier histopathological stage (p = 0.0115) and borderline with smaller tumor size (p = 0.0864). Pancreatic adenocarcinoma patients with enhanced HDAC-1 and −6 expression showed significantly longer survival times compared to those with low expression (p = 0.0022 and p = 0.0113, respectively), while a borderline association concerning HDAC-2 expression was noted (p = 0.0634).ConclusionsThe present study suggested that HDACs may be implicated in pancreatic malignant disease progression, being considered of clinical utility with potential use as therapeutic targets.

【 授权许可】

CC BY   
© Giaginis et al. 2015